RxDoctor Payments Data

Howard Weiss, MD

Ophthalmology · Chevy Chase, MDNPI 1528062502

Payments from drug & device makers

$1,280in general payments, 2019–2025

Across 15 payments — averaging $85.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • NEW World Medical,inc.$390
  • AbbVie$243
  • Bausch & Lomb Americas Inc.$123
  • Apellis Pharmaceuticals, Inc.$117
  • Aerie Pharmaceuticals, Inc.$104
  • Johnson & Johnson Surgical Vision, Inc.$88
  • plus $215 from 4 others

What the payments were for

  • Food & beverage$1,280100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,280 in reported general payments places this provider in the 45th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$454,577
Medicare patients
1,002
Services billed
3,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine29$43,616
LumiganBimatoprost60$36,341
RocklatanNetarsudil Mesylat/Latanoprost26$15,786
Brinzolamide68$11,054
Latanoprost812$10,366
SimbrinzaBrinzolamide/Brimonidine Tart31$10,222
CombiganBrimonidine Tartrate/Timolol23$9,850
VyzultaLatanoprostene Bunod15$8,779
RhopressaNetarsudil Mesylate11$7,301
Travoprost33$6,859
Brimonidine Tartrate137$4,962
Alphagan PBrimonidine Tartrate12$4,499
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat147$3,750
Timolol Maleate347$3,607
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol29$3,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$243$94,305124 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$104$23,08737 claims
AlconSimbrinza$33$10,22231 claims
Bausch & Lomb Americas Inc.Vyzulta$123$8,77915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →